# Infermedica Sp. z o.o.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infermedica-sp-z-o-o

- Industry: Software
- Headquarters: Wroclaw, Poland
- Website: www.infermedica.com
- Total disclosed funding: $40M
- Latest round: Series B (Jan 26, 2022)
- Investors on record: 9

## About

Infermedica is a healthcare technology company specializing in AI-driven tools for symptom checking and virtual triage, aimed at enhancing patient care and operational efficiency in the healthcare sector.Founded in 2012 in Wroclaw, Poland, Infermedica Sp. z o.o. develops healthcare solutions that streamline the patient assessment process. The company has raised a total of USD 30.00 mn, with its most recent funding round being a Series B in January 2022 led by One Peak Partners, along with several returning investors. Piotr Orzechowski is the CEO, and the company was established by Irving Fccp and Roberto Sicconi. Infermedica has completed a total of 9 deals to date.Infermedica offers a range of AI-powered healthcare solutions, with its flagship product being the Symptom Checker. This tool enables users to evaluate their symptoms and receive personalized guidance on care options. The company’s technology is integrated into various platforms, including websites and telemedicine services, and caters to a wide array of clients such as health plans and healthcare providers in over 32 countries. Their offerings are available in 24 languages, optimizing patient engagement and operational efficiency while gathering essential health data.In the most recent fiscal year of 2023, Infermedica reported a revenue of USD 5,008,901.30 and an EBITDA of USD 7,889,691.10. The company operates a revenue model based on subscription services and partnerships, allowing healthcare organizations to integrate their tools effectively into existing systems to improve patient care.Infermedica plans to leverage its recent Series B funding of USD 30.00 mn raised in January 2022 to further its mission of making primary care efficient and affordable through advanced AI technologies. The funds will support the development of new products and enhance existing offerings. The company is targeting expansion into key markets, particularly in North America and Asia, aiming to broaden its reach and impact by the end of 2024.

## Funding rounds

- Series B, Jan 26, 2022, $30M — One Peak, EBRD, Karma Ventures, Inovo VC, Heal Capital
- Series A, Aug 6, 2020, $10M — DreamIt Ventures, Karma Ventures, Inovo VC, European Bank for Reconstruction and Development, Heal Capital
- Seed, Jun 10, 2016 — RTA Ventures
- Seed, Nov 1, 2013, $0.2M — Innovation Nest

## Investors

- Innovation Nest (https://capitalatlas.ai/funds/innovation-nest) — Seed
- RTA Ventures (https://capitalatlas.ai/funds/rta-ventures) — Seed
- DreamIt Ventures (https://capitalatlas.ai/funds/dreamit-ventures) — Series A
- Karma Ventures (https://capitalatlas.ai/funds/karma-ventures) — Series A, Series B
- Inovo VC (https://capitalatlas.ai/funds/inovo-vc) — Series A, Series B
- European Bank for Reconstruction and Development — Series A
- Heal Capital (https://capitalatlas.ai/funds/heal-capital) — Series A, Series B
- One Peak (https://capitalatlas.ai/funds/one-peak) — Series B
- EBRD (https://capitalatlas.ai/funds/ebrd) — Series B